<DOC>
	<DOCNO>NCT00096161</DOCNO>
	<brief_summary>This phase II trial study pentostatin donor lymphocyte infusion prevent graft rejection patient undergone donor stem cell transplant . Giving pentostatin infusion donor 's T cell ( donor lymphocyte infusion ) donor stem cell transplant may stop patient 's immune system reject donor 's stem cell . The donated stem cell may replace patient 's immune cell help destroy remain cancer cell ( graft-versus-tumor effect ) . Sometimes transplanted cell donor also make immune response body 's normal cell . Giving pentostatin donor lymphocyte infusion may stop happening .</brief_summary>
	<brief_title>Pentostatin Lymphocyte Infusion Preventing Graft Rejection Patients Who Have Undergone Donor Stem Cell Transplant</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To assess safety efficacy combine use pentostatin donor lymphocyte infusion ( DLI ) patient low fall donor T-cell chimerism prevent graft rejection transplantation match related donor ( MRDs ) unrelated donor ( URDs ) . SECONDARY OBJECTIVES : I . To determine incidence graft-versus-host disease ( GvHD ) infection disease response , persistent disease present . OUTLINE : This dose-escalation study donor lymphocyte infusion . GROUP I : Patients receive pentostatin intravenously ( IV ) 20-30 minute day -2 DLI 15-30 minute day 0 . Treatment may repeat begin escalated cluster differentiation ( CD ) 3-dose least 4 week persistent donor T-cells document , GvHD develop , chimerism status worsens , chimerism status unchanged least 8 week two subsequent test chimerism 4 week apart . GROUP II ( initiated patient group I achieve sustain engraftment improve chimerism ) : Patients receive treatment group I . Patients also receive cyclosporine orally ( PO ) twice daily ( BID ) day -3 56 mycophenolate mofetil PO daily ( QD ) day 0 27 . Treatment continue absence GvHD . After completion study treatment , patient follow every 6 month 2 year annually thereafter .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Pentostatin</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Patients receive precede allogeneic transplantation either human leukocyte antigen ( HLA ) match related unrelated donor eligible protocol Related donor : HLA genotypically identical least one haplotype may phenotypically genotypically identical allele level HLA A , B , C , DRB1 , DQB1 Unrelated donor prospectively : Matched HLAA , B , C , DRB1 DQB1 high resolution typing ; OR Only single allele disparity allow HLAA , B , C define high resolution type Patients le 50 % donor CD3 peripheral blood chimerism two separate , consecutive evaluation ; two evaluation must least 14 day apart OR patient absolute decrease donor CD3 peripheral blood chimerism &gt; = 20 % second test show &lt; 50 % donor CD3 cell ; two evaluation must least 14 day apart Patients evidence disease eligible disease stable ( persistent ) comparison status prior transplantation Patients must taper systemic steroid dosage less equal 0.25 mg/kg/day Patients must persistent donor CD3 cell ( &gt; = 5 % donor CD3 cell deoxyribonucleic acid [ DNA ] base assay compare profile amplified fragment length polymorphism [ ampFLP ] [ fluorescent situ hybridization ( FISH ) study variable number tandem repeat ( VNTR ) ] ) DONOR : Alternatively fresh unmodified leukapheresis product , previously collect cryopreserved peripheral blood stem cell ( PBSC ) mobilization GCSF cryopreserved unmodified leukapheresis product original donor use ; cryopreserved product available , follow criterion apply DLI product : DONOR : Original donor hematopoietic cell transplantation DONOR : Donor must give consent leukapheresis DONOR : Donor must adequate vein leukapheresis agree placement central venous catheter ( femoral subclavian ) DONOR : Donor must medically fit undergo apheresis procedure ( institutional guideline apheresis ) Current grade II IV acute GVHD extensive chronic GVHD Karnofsky score &lt; 50 % Pediatric criterion Lansky playperformance score &lt; 40 Evidence relapse progression disease transplantation Prior recipient cord blood DONOR : Donors suitable medical reason donate peripheral blood mononuclear cell ( PBMC ) continuous centrifugation accord criterion American Association Blood Banks ( AABB ) DONOR : Pregnancy DONOR : Human immunodeficiency virus ( HIV ) human Tlymphotrophic virus ( HTLV ) infection DONOR : Recent immunization may require delay</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>